Xilio Therapeutics Inc (XLO)

May 29, 2025

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update - Defense World

May 29, 2025

May 25, 2025

Xilio Therapeutics (NASDAQ:XLO) Upgraded at Wall Street Zen - Defense World

May 25, 2025

May 15, 2025

50,086 Shares in Xilio Therapeutics, Inc. (NASDAQ:XLO) Bought by Raymond James Financial Inc. - Defense World

May 15, 2025

May 08, 2025

Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025

May 08, 2025

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart at ASCO 2025, Advancing Tumor-Activated Immuno-Oncology Pipeline - Nasdaq

May 08, 2025

May 08, 2025

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - GlobeNewswire

May 08, 2025

May 06, 2025

Renaissance Technologies LLC Boosts Holdings in Xilio Therapeutics, Inc. (NASDAQ:XLO) - Defense World

May 06, 2025

May 03, 2025

Geode Capital Management LLC Acquires 20,230 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) - Defense World

May 03, 2025

May 02, 2025

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail

May 02, 2025

May 02, 2025

Xilio Therapeutics Awards 5,000 Share Stock Option Grant at $0.755 Per Share to New Employee - Stock Titan

May 02, 2025

May 01, 2025

Xilio’s Stacey Davis recruited by Enara - The Pharma Letter

May 01, 2025

Apr 24, 2025

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting - The Manila Times

Apr 24, 2025

Apr 23, 2025

Xilio Therapeutics to Present Updated Phase 2 Data for - GlobeNewswire

Apr 23, 2025

Apr 23, 2025

Xilio Therapeutics Announces Presentation of Phase 2 Data for Vilastobart and Atezolizumab at 2025 ASCO Annual Meeting - Nasdaq

Apr 23, 2025

Apr 23, 2025

Phase 2 Trial Results: Novel Tumor-Activated Therapy Shows Promise in Hard-to-Treat Colorectal Cancer - Stock Titan

Apr 23, 2025

Apr 14, 2025

Raymond James Financial Inc. Takes Position in Xilio Therapeutics, Inc. (NASDAQ:XLO) - The AM Reporter

Apr 14, 2025

Apr 09, 2025

Xilio Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com India

Apr 09, 2025

Apr 08, 2025

Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com

Apr 08, 2025

Apr 05, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 05, 2025

Apr 04, 2025

Xilio Expands Immuno-Oncology Team: 23K Shares Granted to New Biotech Talent - Stock Titan

Apr 04, 2025

Apr 02, 2025

Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 17.1% in March - Defense World

Apr 02, 2025

Mar 31, 2025

Xilio Therapeutics (XLO) to Release Quarterly Earnings on Monday - Defense World

Mar 31, 2025

Mar 25, 2025

Head to Head Contrast: Xilio Therapeutics (NASDAQ:XLO) and Janone (NASDAQ:ALTS) - Defense World

Mar 25, 2025

Mar 20, 2025

Deals In Depth: February 2025 - insights.citeline.com

Mar 20, 2025

Mar 18, 2025

Xilio Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks

Mar 18, 2025

Mar 12, 2025

Promising Clinical Developments and Strong Financial Outlook Justify Buy Rating for Xilio Therapeutics - TipRanks

Mar 12, 2025

Mar 11, 2025

Xilio advances cancer treatments, secures AbbVie collaboration By Investing.com - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics May Offer, Sell Shares Of Common Stock Of Up To $50 Million From Time To Time - Marketscreener.com

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics inks $50M sales agreement with Leerink Partners - Investing.com India

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics inks $50M sales agreement with Leerink Partners By Investing.com - Investing.com UK

Mar 11, 2025

Mar 11, 2025

Form 424B5 Xilio Therapeutics, Inc. - StreetInsider.com

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 11, 2025

Mar 11, 2025

Xilio advances cancer treatments, secures AbbVie collaboration - Investing.com India

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results - TradingView

Mar 11, 2025

Mar 11, 2025

Xilio Therapeutics Provides Pipeline Progress Update and Anticipates Additional Vilastobart Data in Mid-2025 - Nasdaq

Mar 11, 2025

Mar 04, 2025

Insider Sale Alert: Xilio Therapeutics Inc [XLO] – Is it Time to sell? - Knox Daily

Mar 04, 2025

Feb 28, 2025

Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest - Defense World

Feb 28, 2025

Feb 24, 2025

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times

Feb 24, 2025

Feb 24, 2025

Can Xilio's Novel Immunotherapy Platform Transform Cancer Treatment? CEO Reveals Latest Progress - StockTitan

Feb 24, 2025

Feb 22, 2025

Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 12.3% – Here’s What Happened - Defense World

Feb 22, 2025

Feb 20, 2025

Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie - MSN

Feb 20, 2025

Feb 19, 2025

Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie - Global Legal Chronicle

Feb 19, 2025